dc.contributor.author | Pentheroudakis, George | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Pentheroudakis, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:54:29Z | |
dc.date.available | 2018-06-22T09:54:29Z | |
dc.date.issued | 2006 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42375 | |
dc.description.abstract | Cancer diagnosed during pregnancy constitutes a difficult clinical condition with a devastating impact on the patient's somatic and psychosocial health and possibly on foetal integrity. This circumstance also raises several moral, religious, social and familial dilemmas. In this review we critically present available evidence regarding the incidence, epidemiology and genetics of cancer in pregnant women, its presentation, diagnosis and staging as well as therapeutic management. Issues such as maternal/foetal prognosis, need for termination of pregnancy, risk of foetal health injury and necessity of psychosocial support are reviewed. Recent accumulating evidence suggests that, with appropriate management, poena magna should not be used to define neither cancer nor pregnancy. © 2005 Elsevier Ltd. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | European journal of cancer | en |
dc.subject | Female | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Cisplatin | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Cytarabine | en |
dc.subject | Dacarbazine | en |
dc.subject | Doxorubicin | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Tamoxifen | en |
dc.subject | Vincristine | en |
dc.subject | Humans | en |
dc.subject | Breast cancer | en |
dc.subject | Chemotherapy | en |
dc.subject | Ovary cancer | en |
dc.subject | Priority journal | en |
dc.subject | Prognosis | en |
dc.subject | Bone marrow suppression | en |
dc.subject | Ondansetron | en |
dc.subject | Cancer staging | en |
dc.subject | Cardiotoxicity | en |
dc.subject | Review | en |
dc.subject | Lung cancer | en |
dc.subject | Metastasis | en |
dc.subject | Mother fetus relationship | en |
dc.subject | Neoplasm metastasis | en |
dc.subject | Neoplastic | en |
dc.subject | Pregnancy | en |
dc.subject | Pregnancy complications | en |
dc.subject | Safety | en |
dc.subject | Idarubicin | en |
dc.subject | Imatinib | en |
dc.subject | Pregnancy complication | en |
dc.subject | Retinoic acid | en |
dc.subject | Spontaneous abortion | en |
dc.subject | Teratogenicity | en |
dc.subject | Unindexed drug | en |
dc.subject | Bisphosphonic acid derivative | en |
dc.subject | Brain tumor | en |
dc.subject | Epirubicin | en |
dc.subject | Hypocalcemia | en |
dc.subject | Melanoma | en |
dc.subject | Trastuzumab | en |
dc.subject | Uterine cervix cancer | en |
dc.subject | Side effect | en |
dc.subject | Pamidronic acid | en |
dc.subject | Radiotherapy | en |
dc.subject | Nonsteroid antiinflammatory agent | en |
dc.subject | Disease transmission | en |
dc.subject | Digestive system cancer | en |
dc.subject | Malignant neoplastic disease | en |
dc.subject | Urogenital tract cancer | en |
dc.subject | Cancer | en |
dc.subject | Nonhuman | en |
dc.subject | Anthracycline derivative | en |
dc.subject | Antimetabolite | en |
dc.subject | Practice guideline | en |
dc.subject | Vinca alkaloid | en |
dc.subject | Steroid | en |
dc.subject | Rituximab | en |
dc.subject | Head and neck cancer | en |
dc.subject | Lymphoma | en |
dc.subject | Chlorambucil | en |
dc.subject | Erythropoietin | en |
dc.subject | Metoclopramide | en |
dc.subject | Radiation dose | en |
dc.subject | Analgesic agent | en |
dc.subject | Intrauterine growth retardation | en |
dc.subject | Leukemia | en |
dc.subject | Thyroid cancer | en |
dc.subject | Aminopterin | en |
dc.subject | Fetus disease | en |
dc.subject | Hearing loss | en |
dc.subject | Low birth weight | en |
dc.subject | Psychosocial care | en |
dc.subject | Social support | en |
dc.subject | Pregnancy termination | en |
dc.subject | Stillbirth | en |
dc.subject | Brain malformation | en |
dc.subject | Breast milk | en |
dc.subject | Congenital heart malformation | en |
dc.subject | Foetus | en |
dc.subject | Opiate | en |
dc.subject | Premature labor | en |
dc.subject | Prenatal diagnosis | en |
dc.subject | Treatment contraindication | en |
dc.title | Cancer and pregnancy: Poena magna, not anymore | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/j.ejca.2005.10.014 | |
dc.description.volume | 42 | |
dc.description.issue | 2 | |
dc.description.startingpage | 126 | |
dc.description.endingpage | 140 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 | |